ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Cutaneous manifestations and systemic lupus erythematosus (SLE)
  • Cutaneous manifestations and vasculitis
  • CV-Risk Score
  • CVID
  • CXCL10
  • CXCL13
  • cyclooxygenase
  • cyclooxygenase and prostaglandins
  • cyclophosphamide
  • cyclophosphamide and infection
  • Cyclophosphamide and mycophenolate mofetil
  • cyclophosphamide and neurologic involvement
  • cyclophosphamide and outcomes
  • cyclophosphamide and quality of life
  • cyclophosphamide and rheumatologic disease
  • cyclophosphamide and safety
  • cyclophosphamide and systemic lupus erythematosus (SLE)
  • cyclophosphamide and tuberculosis
  • Cyclophosphamide and vasculitis
  • cyclosporine
  • cyclosporine and lupus nephritis
  • cyclosporine and safety
  • CYR61
  • Cystoid Macular Edema
  • CyTOF
  • CyTOF and integrins
  • CyTOF and monocytes
  • CyTOF and scleroderma
  • CyTOF and systemic lupus erythematosus (SLE)
  • cytokines
  • cytokines and chemokines
  • cytokines and comorbidity
  • Cytokines and dermatomyositis
  • cytokines and environmental factors
  • cytokines and exercise
  • cytokines and familial Mediterranean fever
  • Cytokines and fibroblasts
  • cytokines and flow cytometry
  • cytokines and genetic disorders
  • Cytokines and genomics
  • cytokines and giant cell arteritis
  • cytokines and glomerulonephritis
  • cytokines and heart block
  • cytokines and immunoglobulin (IG)
  • cytokines and inflammasome activation
  • cytokines and inflammation
  • cytokines and inflammatory arthritis
  • cytokines and innate immunity
  • cytokines and interferons
  • cytokines and interleukins (IL)
  • cytokines and Janus kinase (JAK)
  • cytokines and juvenile arthritis
  • cytokines and juvenile dermatomyositis
  • cytokines and longitudinal studies
  • cytokines and lupus nephritis
  • Cytokines and macrophage activation syndrome
  • cytokines and metabolism
  • cytokines and microbiome
  • cytokines and monocytes
  • cytokines and mouse model
  • cytokines and mTor
  • cytokines and mucosal T cells
  • cytokines and myositis
  • cytokines and neonatal disorders
  • cytokines and neuropsychiatric disorders
  • cytokines and osteoarthritis
  • Cytokines and osteoclasts
  • Cytokines and osteoporosis
  • cytokines and pathogenesis
  • Cytokines and plasma cells
  • Cytokines and polymyositis/dermatomyositis (PM/DM)
  • cytokines and posterior reversible encephalopathy syndrome
  • cytokines and proteinuria
  • cytokines and psoriasis
  • cytokines and psoriatic arthritis
  • cytokines and questionnaires
  • cytokines and regulatory cells
  • cytokines and rheumatic disease
  • cytokines and rheumatoid arthritis
  • cytokines and rheumatoid arthritis (RA)
  • cytokines and salivary gland
  • cytokines and signal transduction
  • cytokines and spine involvement
  • cytokines and spondylarthritis
  • cytokines and statins
  • cytokines and synovial cells
  • cytokines and synovitis
  • cytokines and systemic lupus erythematosus (SLE)
  • cytokines and systemic sclerosis
  • cytokines and T cells
  • Cytokines and takayasu arteritis
  • cytokines and tears
  • cytokines and therapeutic targeting
  • cytokines and tocilizumab
  • cytokines and toll-like receptors
  • cytokines and transcription factor
  • Cytokines and vasculitis
  • cytolytic
  • cytopenias
  • Cytotoxic and Gene Expression
  • Cytotoxic Cells
  • cytotoxic lymphocytes and CD319+CD4+
  • DAAs and Relapsers
  • damage
  • damage accrual and High Disease Activity Status
  • damage and Hispanic patients
  • damage and laboratory tests
  • Damage Index
  • Damage Index for APS
  • daratumumab
  • DAS28-CRP and Disease Activity
  • DAS28-ESR
  • Data analysis
  • data analysis and big data
  • data analysis and biologic drugs
  • data analysis and data collection
  • data analysis and Diagnostic Tests
  • data analysis and drug treatment
  • data analysis and fibromyalgia
  • data analysis and gout
  • data analysis and psoriatic arthritis
  • data analysis and synovium
  • data analysis and systemic lupus erythematosus (SLE)
  • data collection
  • data collection and patient health
  • data collection and registry
  • data collection and rheumatoid arthritis (RA)
  • Data Management
  • database
  • DCSTAMP
  • death
  • death and fractures
  • death and health disparities
  • death and metabolic syndrome
  • death and morbidity and mortality
  • death and opioids
  • death and prognostic factors
  • death and rheumatoid arthritis (RA)
  • Death and systemic lupus erythematosus (SLE)
  • death and vasculitis
  • debate and critical appraisal
  • Decision analysis
  • Decision analysis and economics
  • Decision analysis and gout
  • Decision analysis and osteoporosis
  • decision analysis and patient engagement
  • decision analysis and quality of care
  • decision analysis and rheumatoid arthritis
  • decision analysis and rheumatoid arthritis (RA)
  • decision analysis and self-management
  • decision analysis and systemic lupus erythematosus (SLE)
  • decision analysis and treatment options
  • decision conflict
  • Decision Making
  • decline
  • dect
  • Deep Learning
  • Deep neural network
  • deep vein thrombosis and pulmonary embolism
  • Deep venous thrombosis
  • defibrotide
  • Defibrotide and catastrophic antiphospholipid syndrome
  • degenerative arthritis
  • degenerative arthritis and polyarthritis
  • degenerative arthritis and spine involvement
  • degenerative changes
  • Degos Disease
  • Degos Disease and connective tissue diseases
  • Degos Disease and treatment
  • Degos lesions
  • delay in diagnosis
  • delphi
  • Dementia
  • demethylated FoxP3
  • Demographics
  • Dendritic cells
  • dendritic cells and Autoimmune Skin Disease
  • dendritic cells and dermatomyositis
  • dendritic cells and flow cytometry
  • dendritic cells and FLT3L
  • dendritic cells and genetics
  • dendritic cells and glucocorticoids
  • dendritic cells and growth factors
  • dendritic cells and hormones
  • dendritic cells and immune tolerance
  • dendritic cells and inflammation
  • dendritic cells and interferons
  • dendritic cells and interleukins (IL)
  • dendritic cells and lupus nephritis
  • dendritic cells and Macrophage
  • dendritic cells and metabolism
  • dendritic cells and mouse model
  • dendritic cells and natural killer (NK) cells
  • dendritic cells and neuropsychiatric disorders
  • dendritic cells and neutrophils
  • dendritic cells and osteoclastogenesis
  • dendritic cells and pathogenesis
  • dendritic cells and prostaglandins
  • dendritic cells and regulatory cells
  • dendritic cells and rheumatoid arthritis
  • First |
  • « Previous Page
  • 11
  • 12
  • 13
  • 14
  • 15
  • [16]
  • 17
  • 18
  • 19
  • 20
  • 21
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology